Answers are grounded in this paper and cite their sources.
Mycotoxins are structurally diverse fungal secondary metabolites that contaminate food and pose significant carcinogenic risks to humans. However, their molecular interactions with tumor suppressor proteins (p53) remain poorly characterized. This study employed an integrated in silico approach to investigate the potential molecular basis of mycotoxin-induced carcinogenesis through interactions with p53. Five mycotoxins, including Aflatoxins B1 (AFB1), aflatoxins G1 (AFG1), sterigmatocystin (STC), ochratoxin A (OTA), and fumonisin B1 (FB1) were evaluated alongside reference p53 inhibitor, Pifithrin-α (PFT-α). Molecular docking was performed to assess binding affinity and ligand-residue interactions, while DFT (B3LYP/6-31G*) calculations characterized their electronic properties. Pharmacokinetic profiles of the compounds were also evaluated to assess their potential biological fate. Docking revealed favorable p53 binding with binding energies ranging from − 4.9 to -7.4 kcal/mol. AFB1 (∆G = -6.7 kcal/mol), AFG1 (∆G = -6.8 kcal/mol), OTA (∆G = -7.4 kcal/mol) and STC (∆G = -7.0 kcal/mol) showed stronger binding than PFT-α (-5.9 kcal/mol). Pharmacokinetic analysis indicated high absorption, broad distribution, and potential CYP3A4-mediated metabolism. DFT results show wider energy gaps, higher chemical hardness, and electrophilicity, suggesting greater electronic stability, environmental persistence, and potential reactivity towards nucleophilic sites. These findings provide theoretical basis for further experimental investigation of mycotoxin-mediated disruption of p53 signaling.
No takes yet. Share an insight, caveat, or question.
Ameji et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: